Drug intelligence / Profile preview

L002

Development stage: Unknown
Lead developer: Eye Institute of Xiamen University
Administration: Ophthalmic

Overview

L002 is an investigational eye drop being evaluated for the treatment of moderate to severe dry eye. It is currently undergoing clinical trials to assess its safety and efficacy.

Targets

EP300 (Histone acetyltransferase p300 (EP300) catalytic domain)

Beyond the preview

Go deeper on L002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L002.

Explore the full profile